Navigation Links
Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
Date:5/14/2009

Technology to improve accuracy of ovarian cancer diagnosis

TAMPA, Fla., May 14 /PRNewswire/ -- Moffitt Cancer Center and Frantz BioMarkers, LLC have signed a license agreement on phospholipid biomarkers of ovarian cancer. Frantz BioMarkers, which has been granted exclusive worldwide rights to Moffitt's interests in the biomarkers, will pay initiation, developmental milestone and license maintenance fees, and royalties on sales. Moffitt and Frantz BioMarkers will collaborate on ovarian cancer biomarker research, combining use of these licensed markers with lipid markers developed independently by Frantz BioMarkers.

Each year, 26,000 women in the United States are diagnosed with ovarian cancer, and 16,000 die of the disease. There is no effective screening tool or method for accurate diagnosis without surgery. Even among symptomatic women, surgery is the only reliable way to distinguish between benign and malignant disease. It is estimated that up to 5 percent of women in the United States will undergo surgery for a suspected ovarian neoplasm. More than two-thirds of women undergoing surgery for suspected ovarian malignancy do not have cancer.

The only clinical blood biomarker available for diagnosis is CA125, which is unreliable, especially for accurate diagnosis at an early stage when a cure is feasible. Researchers at Moffitt and Frantz BioMarkers discovered that when CA125 is combined with selected phospholipids, the diagnostic accuracy for early stage ovarian cancer can significantly improve. More than 2,200 women donated blood samples for the research through the Tampa Bay Ovarian Cancer Coalition, a collaborative regional network. Frantz BioMarkers is developing these biomarkers into a clinical diagnostic test.

Co-inventors of the technology
'/>"/>

SOURCE Moffitt Cancer Center
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. CMC, Moffitt Partner to Study Cancer
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
10. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Calif.,Nov.25/PRNewswire/-- ChemoCentryx,Inc.,ann...ny,sPROTECT-1(theProspectiveRandomizedOralTherapyE...CX282-B)inpatientswithmoderate-to-severeCrohn,sdis...tyandtolerabilityprofile.Thestudydemonstratedevide...tyasdefinedasa70-pointdecreaseintheCrohn,sDiseaseA...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--Endologix,Inc.(Nasd...oraorticdisorders,announcedtodaythatithasfiledamot...nfringementlawsuitbroughtagainstitinOctober2009byC...CourtinIndianapolis,Indiana. ,, Endologixhasreq...sPatentandTrademarkOffice(USPTO)conductsproceeding...
(Date:11/24/2009)...24/PRNewswire-FirstCall/--AnadysPharmaceuticals,In...the21stAnnualPiperJaffrayHealthcareConferenceonTue...onferenceisbeingheldatTheNewYorkPalaceHotel.SteveW...adys,willprovideanoverviewofAnadysanditsclinicalde...atepresentationwillbesimultaneouslywebcastandcanbe...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2AMT Provides Business Update for the Third Quarter 2009 14895 1AMT Provides Business Update for the Third Quarter 2009 14895 2AMT Provides Business Update for the Third Quarter 2009 14895 3AMT Provides Business Update for the Third Quarter 2009 14895 45 exercises can reduce neck shoulder pain of women office workers 10780 15 exercises can reduce neck shoulder pain of women office workers 10780 25 exercises can reduce neck shoulder pain of women office workers 10780 3BioSoteria CEO to Present at Drug Safety Conference 14889 1BioSoteria CEO to Present at Drug Safety Conference 14889 2
...ENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharma...n of a Phase IIa proof of,concept trial with its l...he study achieved its primary objective, the absen...al significance, and,also showed trends towards im...igraine pain at other time points. ADX10059 has,al...
...ATTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Scie...results of its Phase III,AIR-CF2 study evaluating ... patients with cystic fibrosis (CF) who have,pulmo...e study, a,28-day treatment course of aztreonam ly...nhaled or intravenous (IV) antibiotics versus,plac...
Other Medicine Technology:Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 2Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 3Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7
(Date:11/27/2009)... announced that it has become a national sponsor o...profit organizations dedicated to arthritis resear... Delray Beach, FL (Vocus) November 27, 200...any specializing in the marketing and retail distr...nced today that is has become a national sponsor o...
(Date:11/27/2009)...conomic burdens, study predicts , , FRID...le with diabetes in the United States is expected ...icts. , That would bring the total by 2034 to a... 23.7 million today. , , At the same time, the c...the study also warns, rising from an estimated $11...
(Date:11/27/2009)...announced today that Spectrum Health (Grand Rapids...orthopedic templating solution and its TraumaCad E... (PRWEB) November 27, 2009 -- Voyant Health&trade...ds, Michigan) has licensed its TraumaCad Enterpris... Extend workflow solution, to allow its orthopedic...
(Date:11/27/2009)...ers who use medical load cells at the heart of the...ging in technology partner Flintec early in the de...ical manufacturers are calling in Flintec load cel...ensuring that progress will not be constrained by ...technology. , (PRWEB) Nov...
(Date:11/26/2009)...fluseasonuponus,it,smoreimportantthanevertoemployg...illness. ,, "Weneedtobeproactivenotonlytokeepou...esick,"saidEileenFinerty,RN,MS,CIC(certifiedininfe...ndoccupationalhealthatHospitalforSpecialSurgery(HS...neofthelowestinfectionratesofanyhospitalinthecount...
Breaking Medicine News(10 mins):Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3
...ELPHIA (January 22, 2008) -- Researchers from the ...have used a novel molecular method to identify che...man bitter taste receptors. , The findings, publ...ste in particular. , Identification of bitter t...
...chers in the Department of Medicine and Department...e have discovered that chronic pain can be success... an effort to find a more effective treatment for ...ensory neuron targeting by self-complementary AAV8...
...da, MD (Jan. 18, 2008) The use of regular, long-t...ugs (NSAIDs) reduces the risk associated with colo...Gastroenterology , the official journal of the Ame... at doses that are higher than recommended over a ...
...l, January 22, 2007 An international research tea...de lUniversit de Montral (CHUM), has identified ne...e sclerosis (MS). In the February issue of Nature ... the nervous system that affects approximately 55,...
...dies sense painful stimuli through certain recepto...l organs. Specialized nerve fibers relay these sig... pain becomes conscious. The spinal cord is placed...nd at the Institute of Pharmacology and Toxicology...
...taking Nexavar need to be monitored closely, study...) -- ,A drug that prolongs the lives of patients w... of developing high blood pressure. , Patients ta...logy . , Nexavar is an anti-angiogenesis drug, mea...
Other Medicine News:Health News:Food peptides activate bitter taste receptors 2Health News:Researchers find relief for chronic pain 2Health News:Regular, long-term aspirin use reduces risk of colorectal cancer 2Health News:New therapeutic target for treatment of multiple sclerosis 2Health News:Nature publication on pain research 2Health News:Liver Cancer Drug Raises Blood Pressure 2
Atria 3100 ECG
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: